| References: |
MI-773 binds to MDM2 with Ki of 0.88 nM. MI-773 potently inhibits cell growth in cancer cell lines, including SJSA-1 (IC50, 0.092 μM), RS4;11 (IC50, 0.089 μM), LNCaP (IC50, 0.27 μM), and HCT-116 (IC50, 0.20 μM) cells, and displays high selectivity over cancer cell lines with mutated or deleted p53, including SAOS-2 (IC50, >10 μM), PC-3 (IC50, >10 μM), SW620 (IC50, >10 μM), and HCT-116 (p53-/-) (IC50, >20 μM) cells. In the SJSA-1 osteosarcoma, acute lymphoblastic leukemia RS4;11, LNCaP prostate cancer, and HCT-116 colon cancer xenograft model, MI-773 (p.o.) effectively inhibits tumor growth in a dose-dependent manner (10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg,). For the detailed information of MI-77301 (SAR405838), the solubility of MI-77301 (SAR405838) in water, the solubility of MI-77301 (SAR405838) in DMSO, the solubility of MI-77301 (SAR405838) in PBS buffer, the animal experiment (test) of MI-77301 (SAR405838), the cell expriment (test) of MI-77301 (SAR405838), the in vivo, in vitro and clinical trial test of MI-77301 (SAR405838), the EC50, IC50,and affinity,of MI-77301 (SAR405838), For the detailed information of MI-77301 (SAR405838), the solubility of MI-77301 (SAR405838) in water, the solubility of MI-77301 (SAR405838) in DMSO, the solubility of MI-77301 (SAR405838) in PBS buffer, the animal experiment (test) of MI-77301 (SAR405838), the cell expriment (test) of MI-77301 (SAR405838), the in vivo, in vitro and clinical trial test of MI-77301 (SAR405838), the EC50, IC50,and affinity,of MI-77301 (SAR405838), Please contact DC Chemicals. |
